Ablexis
San Francisco
California
United States
Tel: 415-978-2177
Fax: 415-978-1929
Website: http://www.ablexis.com/
Email: info@ablexis.com
29 articles with Ablexis
-
Ablexis Announces License Agreement with Adimab
2/9/2023
Ablexis, LLC today announced a license agreement with Adimab, LLC (“Adimab”).
-
Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities
11/15/2022
Ablexis, LLC and AlivaMab Discovery Services, LLC announced an expansion of platforms and capabilities in antibody drug discovery and engineering.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development
1/31/2022
Ablexis, LLC and AlivaMab Discovery Services, LLC announced a multi-target licensing agreement between Ablexis and Almirall, S.A., a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall.
-
Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A.
5/4/2021
Ablexis grants rights to use the AlivaMab ® Mouse platform for research, development and commercialization of antibodies
-
Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies
4/22/2020
Ablexis, LLC , AlivaMab Discovery Services, LLC ("ADS") and Berkeley Lights, Inc. today announced the rapid generation and recovery of sequences encoding a rich panel of human antibodies against the S1 spike protein of the S
-
Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US)
6/3/2019
Ablexis grants rights to use the AlivaMab™ Mouse platform for research, development and potential commercialization of antibodies
-
Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company
1/17/2019
Expanded rights enable broader use of AlivaMab Mouse™ platform
-
Ablexis Announces Licensing Agreement with Corvidia Therapeutics
1/3/2019
Ablexis grants rights to Corvidia to use the AlivaMab Mouse™ platform for research, development and potential commercialization of antibodies
-
Ablexis Announces Licensing Agreement with Allogene Therapeutics
12/6/2018
Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform
-
Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering
11/13/2018
Issued claims cover unique features of AlivaMab Mouse, AlivaMab antibodies and immunoglobulin transgene construction and compositions
-
Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development
11/5/2018
Further validates efficiency of AlivaMab Mouse for antibody drug discovery and development
-
Ablexis Announces Licensing Agreement with Voyager Therapeutics
10/23/2018
Ablexis grants rights to Voyager to use the AlivaMab Mouse platform for research, development and potential commercialization of antibodies
-
Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center
10/9/2018
Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse Platform
-
Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals
1/5/2018
The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.
-
Ablexis Announces Licensing Of The Alivamab Mouse To Five Prime
9/14/2017
-
Ablexis Announces Perpetual License Agreement For Alivamab Mouse With Janssen Biotech
2/14/2017
-
Ablexis Release: Company Announces Perpetual License Of The Alivamab Mouse To Tri-Institutional Therapeutics Discovery Institute
1/12/2017
-
Ablexis Announces Perpetual License Of The Alivamab Mouse To A Top 15 Pharma
7/20/2016
-
Ablexis Announces Perpetual License Of The Alivamab Mouse To A Top 15 Pharm
3/22/2016